GSK plc (BVMF:G1SK34)
Brazil
· Delayed Price · Currency is BRL 51.95
+1.00 (1.96%)
At close: Dec 4, 2025
Revenue
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2013 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2013 - 2020 |
| HIV Revenue | 7.51B | 7.09B |
Log In |
Log In |
Log In | Upgrade
|
| Respiratory, Immunology and Inflammation Revenue | 3.63B | 3.30B |
Log In |
Log In |
Log In | Upgrade
|
| Oncology Revenue | 1.82B | 1.41B |
Log In |
Log In |
Log In | Upgrade
|
| Pandemic Revenue | - | - |
Log In |
Log In |
Log In | Upgrade
|
| Specialty Medicines Revenue | 12.97B | 11.81B |
Log In |
Log In |
Log In | Upgrade
|
| Shingles Revenue | 3.40B | 3.36B |
Log In |
Log In |
Log In | Upgrade
|
| Meningitis Revenue | 1.57B | 1.44B |
Log In |
Log In |
Log In | Upgrade
|
| Influenza Revenue | 328.00M | 408.00M |
Log In |
Log In |
Log In | Upgrade
|
| Established Vaccines Revenue | 3.23B | 3.34B |
Log In |
Log In |
Log In | Upgrade
|
| Pandemic Vaccines Revenue | - | - |
Log In |
Log In |
Log In | Upgrade
|
| Vaccines Revenue | 9.08B | 9.14B |
Log In |
Log In |
Log In | Upgrade
|
| Respiratory Revenue | 7.09B | 7.21B |
Log In |
Log In |
Log In | Upgrade
|
| Other General Medicines Revenue | 3.03B | 3.22B |
Log In |
Log In |
Log In | Upgrade
|
| General Medicines Revenue | 10.12B | 10.43B |
Log In |
Log In |
Log In | Upgrade
|
| Total Commerical Operations Revenue | 32.17B | 31.38B |
Log In |
Log In |
Log In | Upgrade
|
| Revenue (Other) | - | -31.38B |
Log In |
Log In |
Log In | Upgrade
|
| Revenue (Total) | - | 31.38B |
Log In |
Log In |
Log In | Upgrade
|
Revenue by Geography
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2013 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2013 - 2020 |
| US Revenue | 16.74B | 16.38B |
Log In |
Log In |
Log In | Upgrade
|
| Europe Revenue | 7.22B | 6.67B |
Log In |
Log In |
Log In | Upgrade
|
| International Revenue | 8.20B | 8.33B |
Log In |
Log In |
Log In | Upgrade
|
| Revenue (Total) | - | 31.38B |
Log In |
Log In |
Log In | Upgrade
|
EBIT
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2013 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2013 - 2020 |
| Commercial Operations Segment Profit | 15.86B | 15.34B |
Log In |
Log In |
Log In | Upgrade
|
| Research & Development Segment Profit | -6.10B | -5.85B |
Log In |
Log In |
Log In | Upgrade
|
| Operating Income (Other) | - | -5.47B |
Log In |
Log In |
Log In | Upgrade
|
| Operating Income (Total) | - | 4.02B |
Log In |
Log In |
Log In | Upgrade
|